文摘
客观的我们调查基线之间可能的联系的临床、电生理学和成像测量的急性视神经炎(AON), 6个月后,轴突丧失的程度。背景怡安是一种常见的多发性硬化的表现neuroaxonal变性可能导致持续的视觉缺陷。判断预后的临床和病理因素发病没有充分的特点。设计/方法II期临床试验的86名参与者神经保护与苯妥英怡安了一个意味着症状出现后的8天。视觉功能(logMAR,对比灵敏度低,Farnsworth-Munsell 100色调色彩感知来衡量),光学相干断层扫描(视网膜神经纤维层(RNFL)厚度、黄斑体积),电生理学(VEP延迟、振幅)和视神经MRI(视神经lesional长度、横截面积)获得的基线,和之后6个月。皮尔森相关系数和多元线性回归是用来识别基线测量之间的关联和RNFL厚度6个月。结果在安慰剂组,大基线RNFL厚度的影响,当调整基线影响RNFL厚度(即影响RNFL肿胀程度),与最终RNFL变薄(r = -0.34, p = 0.03);这不是观察到活性组(r = -0.08, p = 0.639)。同样在安慰剂组,基线VEP延迟负相关(r = -0.39, p = 0.010),并基线幅度呈正相关(r = 0.37, p = 0.017),最终RNFL变薄;结果类似的活动组。也有重大的负面联想安慰剂和活跃的团体之间的基线logMAR敏锐度,Farnsworth-Munsell 100色相误差值,最后RNFL变薄。没有明显的低对比度灵敏度基线或MRI病灶之间的关联特征,和RNFL变薄。结论这个队列研究的结果后不久出现怡安确认和扩展先前的发现,和表明,测量反射强度的急性炎症,甚至髓鞘脱失,与轴突退化有关。
披露:Raftopoulos博士没有披露。西克曼博士没有披露。Toosy博士已经收到个人活动与生原体补偿Idec。Sharrack博士没有披露。Mallik博士没有披露。木栅博士已经收到个人补偿活动梯瓦制药。•阿尔特曼博士没有披露。Yiannakas博士没有披露。Malladi博士没有披露。谢里丹博士没有披露。 Dr. Sarrigiannis has nothing to disclose. Dr. Hoggard has nothing to disclose. Dr. Koltzenburg has received personal compensation from Pfizer, GlaxoSmithKline, Inc., and Merck Pharma. Dr. Koltzenburg has received research support from Pfizer. Dr. Wheeler-Kingshott has received personal compensation for activities with Biogen Idec as a consultant. Dr. Wheeler-Kingshott has received research support from the UK MS Society, UCL/UCLH, NIHR, BRC, EPSRC, ISRT, Wings for Life, and New Zealand Brain R Dr. Schmierer has received personal compensation for activities with Roche, Biogen, Teva, and, Novartis. Dr. Giovannoni has received personal compensation for activities with AbbVie Biotherapeutics Inc., Biogen, Bayer HealthCare, Genzyme, Merck Serono, Sanofi-Aventis, Teva, Ironwood, and Novartis. Dr. Miller has nothing to disclose. Dr. Kapoor has received personal compensation for activities with National Multiple Sclerosis Society, Multiple Sclerosis Society of GB&NI, and Novartis.
周二,2016年4月19日,8:30 am-7:00点
- 版权©2016年长企业公司,。
